NEW YORK (GenomeWeb News) – Cenix BioScience said today it will work with the drug developer AstraZeneca in a tailored RNAi research collaboration aimed at advancing oncology drug targets.
 
Under the agreement, Cenix will combine its RNAi-based gene silencing technology with phenotypic analyses in cultured human cells. The research program will initially involve a high-throughput RNAi screen using an assay that the companies will design together to find and validate novel targets for cancer treatments.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The New York Times reports that genetic testing has uncovered unfaithful penguins at a Utah aquarium.

Cancer researcher loses funding under new Wellcome Trust anti-bullying policies, the Guardian reports.

In Science this week: International Wheat Genome Sequencing Consortium publishes the bread wheat cultivar Chinese Spring reference genome, and more.

At his FDA Law Blog, Jeffrey Gibbs discusses FDA's technical assistance for the draft Diagnostic Accuracy and Innovation Act.